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Defining a “dedicated” breast cancer team
N. Maliko1, N. Bijker2, M. Wouters1, M.J. Vrancken-Peeters1. 1Antoni van
Leeuwenhoek, Surgical Oncology, Amsterdam, Netherlands; 2Amsterdam
Universitair Medische Centra, Radiotherapy, Amsterdam, Netherlands
Background: The quality of breast cancer (BC) care in the Netherlands is
high. All patients are discussed in pre- and post-operative multidisciplinary
meetings and treated by certifiedmedical specialists. Some characteristics of
the medical team and the organization involved in BC care are monitored in
the national multidisciplinary NABON breast Cancer Audit (NBCA) by quality
indicators measuring the structure of the teams. The scientific committee of
the NBCA is responsible for the multidisciplinary set of quality indicators. For
some quality indicators variation is seen. The aim of this study was to explore
if the presence of a defined “dedicated” BC team influences this variation.
Material and Methods:We chose the following characteristics at hospital
level to define a “dedicated” BC team: minimum of 50 new BC patients per
year, two certified surgical oncologists who treat BC patients, two certified
internist oncologists who treat BC patients, one plastic surgeon who treats
BC patients, plastic surgeon participating standard in multidisciplinary
meeting, radiotherapist participating standard in multidisciplinary meeting,
PALGA protocol (synoptic pathology reporting) being used, the median time
between diagnosis and surgery (excluding direct reconstruction) being ≤30
days. The composite measure “dedicated” BC team was used to assess if a
“dedicated” BC team influences the outcomes of quality indicators.
Table 1
6 criteria 7 criteria 8 criteria








Results: In 2017 83 hospitals registered their BC patients in the NBCA.
75.9% (n = 63) fromall the hospitalsmeet all criteria of a “dedicated”BC team.
19 (22.9%) hospitals meet seven and one hospital meets six (1.2%) criteria.
The results show that hospitals that meet all the criteria of a “dedicated”
breast cancer team scored on average higher on the quality indicators
preserving breast contour, breast MRI performed in patients treated with neo-
adjuvant chemotherapy (NAC), and consultation with the radiotherapist
within 28 days after start NAC, comparedwith hospitals thatmeet seven or six
criteria (Table 1).
Conclusion: The results suggest that defining a “dedicated” BC team and
motiving hospitals to develop these treatment teams can lead to better
outcomes of BC care.
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Predictive factors involved in determining response to neoadjuvant
chemotherapy in breast cancer and impact of response on 5 years
disease free survival and overall survival
B. Rehman1, M.A. Parvaiz1. 1Shuakat Khanum Memorial Cancer Hospital
and Research Center Lahore, Breast and Oncoplastic, Lahore, Pakistan
Background: The advantages of Neo-Adjuvant chemotherapy (NAC) are
more breast conservation surgeries and ability to monitor treatment response
in vivo. Not all patients respond well to NAC in term of tumor size reduction
and lymph nodal response. The goal of the study is to identify all the known
factors that may play a role in predicting response to chemotherapy, thus
identifying a group of patients which would be resistant to NAT and thus
potential harmful effects are avoided in that subset of patients.
Material and Methods:We retrospectively reviewed data from Jan 2012 to
Dec 2012 in a single center in Shaukat Khanumhospital Lahore, Pakistan. All
thosewho receivedNAC (as theywere not candidates for upfront surgery) and
having no distantmetastasis were included. 156 patients were studied. Tumor
grade, receptor status, menopausal status, family h/o ca breast, parity, initial T
and N stagewere studied as predictive factors for response to chemotherapy.
HER-2 Neu positivity was not considered as only 2 patients received
Transtuzumab. The response was measured in term of percentage reduction
from 1st radiological size on presentation to final size on histopathology (on
resected specimen). Four groups were identified, complete responder group
with 100% reduction, Non responder group, Partial responder PR (<50%
reduction), Responders R (>50% reduction). 5 year disease free survival,
overall survival and recurrence were noted for each group.
Results: Mean Age was 47 years. 96% of patients were invasive ductal
carcinoma, rest were lobular. 57% of patients were grade III, 90% of patients
were T2 and 66% were LN positive (both at presentation). 67% of patients
underwent BCS (Breast conserving surgery) rest underwent Mastectomy.
Mortality for whole group was 19%, and recurrence was shown in 30%
(Majority was distant 26%, while contralateral were 3%). Out of 156 patients,
25% of patients were complete responders, 13% were non responders, 23%
were partial responder (<50% reduction) and 37% were responders (>50%
response). ER and PR negative Tumors and Grade III tumors showed more
complete responses. Rest of factors, including triple negative, Initial T and N
stage and other factors showed no impact on chemo-response. Survival was
significantly poor in non responder group (45%OS, 40%DFS), while rest of 3
groups had comparable survival outcome, with complete responder group
having best survival outcome (86% OS, 80% DFS).
Conclusion: Only ER and PR negative tumors and grade 3 tumors
showed more complete response. Survival outcomes were significantly poor
in Non-responders while it was better in complete responders.
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Male breast cancer: A high volume centre experience
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G. Tazzioli2. 1University of Modena and Reggio Emilia, PHD Clinical and
Experimental Medicine, Modena, Italy; 2Azienda Ospedaliero Universitaria
Policlinico di Modena, Breast Unit, Modena, Italy; 3University of Modena and
Reggio Emilia, Scuola di Specializzazione in Chirurgia Generale, Modena,
Italy
Background: Male breast cancer (MBC) accounts for less than 1% of all
cancers in men. Several genetic disorders, such as Lynch, Cowden,
Klinefelter and Li-Fraumeni syndrome contribute to increase the lifetime
risk to develop breast cancer in males.
In general population, the lifetime risk for MBC is 0.1%, but it rises to 7–8%
with a BRCA2 mutation and 1% with a BRCA1 mutation.
Material and Methods: We describe the surgical experience of a single
high volume center (Breast Surgical Oncology Unit of Modena University
Hospital) from 2006 to 2019.
Results: We treated 29 patient with MBC.
Median age at diagnosis was 64 years (minimum 45 to maximum 84).
Aminority of patients presented with bilateral disease at the onset (10.3%).
Most patients (75.1%) had retroareolar tumor.
41.4% had significant familiar history for breast cancer. Genetic testing
was performed in all patients, but only 26.1% was positive for BRCA2
mutation. No BRCA1 mutation was found.
All the patients underwent simple mastectomy. The 3.4% had distant
metastasis, but surgery was performed for local control of the disease.
We performed immediate axillary dissection in 21.8% of patient for nodal
positivity at the time of diagnosis; the remaining were treated with sentinel
node biopsy and only three of them underwent following axillary dissection
for sentinel node positivity.
No significant post-operative complications were observed and medial
hospital stay was two days.
At the final histology ductal carcinoma was found in all breasts, in only one
specimen lobular carcinoma coexisted with the ductal one.
Almost all cases showed intermediate or high grade disease (G2-G3).
None of patients had triple negative cancer; c-erbB2 positivity was found in
only 8%, the rest of tumors were luminal-like.
In addition to surgery 10.9% of patients received neoadjuvant chemother-
apy, 24.1% adjuvant chemotherapy and 82.8% endocrine therapy, mostly
tamoxifen.
Radiotherapy was applied in locally advanced disease, in one case for the
treatment of nodal recurrence and in another case on bone metastasis.
Conclusions: Our experience does not differ from other case series
described in literature in terms of epidemiological, histopathological and
genetic findings.
From a surgical point of view we confirmed radical mastectomies as the
preferred choice of resection. Sentinel node biopsy is safe and feasible in
men as in women. Post-operative course in men is similar to women’s one
and also oncological adjuvant strategy is chosen following the same
guidelines.
To achieve optimal management of male breast cancer, patients must be
centralized to a hospital with a breast unit, to give the possibility of genetic
counseling and to share with the multidisciplinary team every step of both
diagnostic and therapeutic phases.
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